Every vaccine has one job: show your immune system what a pathogen looks like before it encounters the real thing. But how it does that job differs sharply across platforms. Inactivated vaccines present a killed whole virus, mRNA vaccines hand your own cells temporary genetic instructions, and viral vector vaccines use a harmless modified virus to ferry antigen-coding genes inside. Those mechanistic differences drive the other differences you care about: how fast a vaccine can be developed, how it is manufactured, and which arms of the adaptive immune system it activates.

Understanding Vaccine Technologies: A Comparative Overview

Vaccinology began with platforms like Jenner's smallpox vaccine and Salk's polio vaccine, according to a review in Exploration of Immunology, before expanding into subunit, protein-based, viral vector, and messenger RNA approaches. As a review in PMC on novel vaccine approaches puts it, all vaccines work by "exposing a subject to a part or whole pathogen, thus activating the immune system." The distinction between platforms is in what exactly is exposed, and where.

A Nature Reviews Immunology guide by Andrew Pollard and Else Bijker offers a useful taxonomy: vaccines are generally classified as live or non-live, separating attenuated replicating strains from vaccines containing "only components of a pathogen or killed whole organisms." Beyond those traditional categories, newer platforms include viral vectors and nucleic acid-based RNA and DNA vaccines. The three we compare here—mRNA, viral vector, and inactivated—sit on both sides of that divide.